Company Encyclopedia
View More
name
SDKX
688136.SH
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b inhalation solution that is in Phase III clinical trial; GB-K02, an human granulocyte colony-stimulating factor injection in Phase III clinical trial; GB08, an growth hormone that has completed Phase I clinical trial; GB10 for fundus diseases; GB12 for atopic dermatitis; GB18 for cancer cachexia; GB23 for solid tumors; GB24 for inflammatory bowel diseases; and GB25, an tri-specific antibody for colorectal cancer. In addition, the company’s products include drugs, such as human erythropoietin, human interferon a1b and human granulocyte colony-stimulating factor injections, albumin-bound paclitaxel, infliximab injection, combined clostridium butyricum, and bifidobacterium powder/capsule.
1.601 T
688136.SHMarket value -Rank by Market Cap -/-

Financial Score

07/11/2025 Update
B
BiotechnologyIndustry
Industry Ranking10/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.54%B
    • Profit Margin8.28%B
    • Gross Margin63.73%A
  • Growth ScoreB
    • Revenue YoY14.15%B
    • Net Profit YoY205.70%A
    • Total Assets YoY13.70%B
    • Net Assets YoY5.91%B
  • Cash ScoreB
    • Cash Flow Margin1207.58%B
    • OCF YoY14.15%B
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreC
    • Gearing Ratio49.69%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SDKX: The first subject has been enrolled in the Phase I clinical trial of GB18 injection

    Sinovac Biotech announced that its wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd., has successfully completed the first subject enrollment and administration in the Phase I clinical study of "GB18 Injection."

    Zhitong·
    SH
    688136
    -0.89%
    Zhitong·
    SH
    688136
    -0.89%

    Caitong Securities: The demand for phosphonamide monomers will flourish, and multinational pharmaceutical companies' supply chain enterprises are expected to benefit

    Caitong Securities released a research report indicating that phosphoramidite monomers play a key role in the development of small nucleic acid drugs, and demand is expected to grow significantly in the future. According to predictions from sphericalinsights, global sales of nucleotides will reach USD 730 million in 2023, with China being the largest production market, primarily focused on exports. Small nucleic acid drugs are considered potential treatment options for various diseases due to their unique molecular structure and therapeutic mechanisms, and companies within the supply chains of multinational pharmaceutical companies are expected to benefit from this

    Zhitong·
    SH
    688566
    -2.25%
    SH
    688136
    -0.89%
    SZ
    002250
    +10.01%
    Zhitong·
    SH
    688566
    -2.25%
    SH
    688136
    -0.89%
    SZ
    002250
    +10.01%

    SDKX and EASTON BIOPHARMACEUTICALS jointly expand the overseas market for Apalutamide tablets

    Sinovac Biotech has signed a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. Recently, both parties reached an exclusive overseas commercialization authorization for Easton Biopharmaceuticals' Apalutamide tablets in more than ten countries, including Indonesia, Egypt, Saudi Arabia, and Colombia, further deepening their cooperation and promoting this heavyweight drug in the field of prostate cancer treatment to enter potential markets in Southeast Asia, the Middle East, and Latin America

    Zhitong·
    SH
    688513
    -2.66%
    SH
    688136
    -0.89%
    Zhitong·
    SH
    688513
    -2.66%
    SH
    688136
    -0.89%

    SDKX and IM Motors will collaborate to develop macromolecular drugs

    On October 10th, SDKX announced that the company has recently signed a cooperation agreement with the macromolecule drug development CDMO company Zhixiang Biotechnology Co., Ltd., and the two parties will collaborate on the development of macromolecule drugs

    Zhitong·
    SH
    688136
    -0.89%
    Zhitong·
    SH
    688136
    -0.89%

    The "A+H" stock craze continues, with 76 A-share companies filing applications to go public in Hong Kong

    On September 30th, CSPC Innovation, SDKX, and COOLTECH POWER announced plans to list in Hong Kong. As of now, according to incomplete statistics from reporters, since September, 25 A-share listed companies have announced plans to list in Hong Kong. In addition, Wind data shows that as of October 2nd, 76 A-share listed companies have submitted applications to the Hong Kong Stock Exchange and are waiting for hearings

    Zhitong·
    SZ
    300765
    -2.76%
    SH
    688136
    -0.89%
    SZ
    300153
    -3.19%
    Zhitong·
    SZ
    300765
    -2.76%
    SH
    688136
    -0.89%
    SZ
    300153
    -3.19%